INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,948,550 | -17.7% | 95,000 | 0.0% | 0.53% | -15.8% |
| Q2 2023 | $6,015,400 | +2.2% | 95,000 | -9.5% | 0.63% | -1.9% |
| Q1 2023 | $5,885,250 | -11.0% | 105,000 | -16.0% | 0.65% | -6.4% |
| Q4 2022 | $6,615,000 | +15.9% | 125,000 | 0.0% | 0.69% | +15.4% |
| Q3 2022 | $5,709,000 | -28.6% | 125,000 | -10.7% | 0.60% | -34.1% |
| Q2 2022 | $7,991,000 | -53.4% | 140,000 | -50.0% | 0.91% | -46.3% |
| Q1 2022 | $17,133,000 | -15.7% | 280,000 | -28.2% | 1.69% | +25.0% |
| Q4 2021 | $20,331,000 | +26.9% | 390,000 | -9.2% | 1.35% | +20.3% |
| Q3 2021 | $16,020,000 | -8.7% | 429,728 | 0.0% | 1.12% | -5.6% |
| Q2 2021 | $17,541,000 | +12.9% | 429,728 | -6.1% | 1.19% | +10.0% |
| Q1 2021 | $15,532,000 | -2.3% | 457,778 | -8.4% | 1.08% | -16.5% |
| Q4 2020 | $15,900,000 | +30.4% | 500,000 | +5.3% | 1.30% | +19.6% |
| Q3 2020 | $12,189,000 | -0.0% | 475,000 | 0.0% | 1.08% | -17.7% |
| Q2 2020 | $12,193,000 | +39.8% | 475,000 | -16.3% | 1.32% | +7.8% |
| Q1 2020 | $8,723,000 | -49.2% | 567,534 | +13.5% | 1.22% | -35.0% |
| Q4 2019 | $17,155,000 | +170.2% | 500,000 | -41.2% | 1.88% | +136.2% |
| Q3 2019 | $6,350,000 | -48.5% | 850,000 | -10.5% | 0.80% | -41.4% |
| Q2 2019 | $12,329,000 | +6.6% | 949,833 | 0.0% | 1.36% | +0.4% |
| Q1 2019 | $11,569,000 | +53.9% | 949,833 | +43.9% | 1.35% | +57.5% |
| Q4 2018 | $7,517,000 | -47.1% | 659,982 | +0.8% | 0.86% | -39.7% |
| Q3 2018 | $14,213,000 | +15.4% | 654,982 | -6.0% | 1.42% | +13.0% |
| Q2 2018 | $12,315,000 | -26.2% | 696,957 | -12.1% | 1.26% | -38.7% |
| Q1 2018 | $16,687,000 | +6.3% | 792,730 | -26.9% | 2.06% | -3.1% |
| Q4 2017 | $15,705,000 | -15.7% | 1,084,581 | -8.1% | 2.12% | -10.7% |
| Q3 2017 | $18,619,000 | +79.9% | 1,179,900 | +41.6% | 2.38% | +60.0% |
| Q2 2017 | $10,348,000 | -11.0% | 833,154 | +16.4% | 1.49% | -19.3% |
| Q1 2017 | $11,630,000 | +165.8% | 715,664 | +146.8% | 1.84% | +119.5% |
| Q4 2016 | $4,376,000 | -99.8% | 290,000 | +114.8% | 0.84% | +156.6% |
| Q3 2016 | $2,057,400,000 | +45988.7% | 135,000 | +17.4% | 0.33% | -58.8% |
| Q2 2016 | $4,464,000 | +39.6% | 115,000 | 0.0% | 0.79% | +24.9% |
| Q1 2016 | $3,197,000 | -52.8% | 115,000 | -8.7% | 0.64% | -38.0% |
| Q4 2015 | $6,778,000 | +2.6% | 126,000 | -23.6% | 1.02% | -2.7% |
| Q3 2015 | $6,607,000 | +0.4% | 165,000 | -19.9% | 1.05% | +33.3% |
| Q2 2015 | $6,582,000 | +50.6% | 206,000 | +12.6% | 0.79% | +7.2% |
| Q1 2015 | $4,370,000 | +54.9% | 183,000 | +14.5% | 0.74% | -9.9% |
| Q4 2014 | $2,821,000 | +38.1% | 159,854 | +7.3% | 0.82% | +36.8% |
| Q3 2014 | $2,043,000 | +23.3% | 149,000 | +51.6% | 0.60% | +21.5% |
| Q2 2014 | $1,657,000 | -7.3% | 98,269 | 0.0% | 0.49% | -8.2% |
| Q1 2014 | $1,787,000 | – | 98,269 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |